Group 1 - The company, Chengda Biology, announced on September 1 that it has repurchased a total of 176,421 shares through the Shanghai Stock Exchange trading system, which represents approximately 0.042% of the company's total share capital [2]

Core Viewpoint - Chengda Biological announced plans to hold a semi-annual performance briefing on September 10, 2025 [2] Company Summary - Chengda Biological will conduct a performance briefing to discuss its financial results for the first half of 2025 [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/19 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 月 19 | 6 | 日~2026 | 年 | 6 月 | 18 | 日 | | 预计回购金额 | 万元~2,000 1,000 | | 万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 股 176,421 | | | | | | | | 累计已回购股数占总股本比例 | 0.042% | | | | | | | | 累计已回购金额 | 5,041,082.86 | | | 元（不含交易费用和佣金） | | | | | 实际回购价格区间 | 元/股~29.61 27.82 | | ...

证券代码：688739 证券简称：成大生物 公告编号：2025-049 辽宁成大生物股份有限公司 关于召开 2025 年半年度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 9 月 3 日（星期三）至 9 月 9 日（星期二）16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lncdsw@cdbio.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 辽宁成大生物股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日发布公 司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度 的经营成果、财务状况，公司计划于 2025 年 9 月 10 日上午 9:00-10:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 业绩说明会类型 本次投资者说明会以网络互动形式召开，公 ...

格隆汇9月1日丨成大生物(688739.SH)公布，截至2025年8月31日，公司通过上海证券交易所交易系统以 集中竞价交易方式已累计回购公司股份176,421股，占公司总股本的比例约为0.042%，回购成交的最高 价为29.61元/股，最低价为27.82元/股，已支付的资金总额为人民币5,041,082.86元（不含交易费用和佣 金）。 ...

国家知识产权局信息显示，成大生物（本溪）有限公司取得一项名为"一种适用于超滤系统气密性检测 装置"的专利，授权公告号CN 223272095 U，申请日期为2024年11月。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 专利摘要显示，本实用新型提供一种适用于超滤系统气密性检测装置，属于气密性检测技术领域，以解 决现有的适用于超滤系统气密性检测装置，减压阀、空气滤芯外壳密封、压缩空气气管及气管接口处会 有漏气的风险，减压阀泄压较为缓慢的问题。包括检测台；控制面板，所述控制面板固定安装在检测台 顶部；空气过滤箱，所述空气过滤箱固定安装在检测台内部；密封盖，所述密封盖卡扣连接在空气过滤 箱一侧；四通旋塞阀，所述四通旋塞阀固定安装在控制面板前侧；空气滤芯，所述空气滤芯卡接在空气 过滤箱内部泄压组件所述泄压组件设置在检测台上部维护组件，所述维护组件设置在检测台内部。 天眼查资料显示，成大生物（本溪）有限公司，成立于2021年，位于本溪市，是一家以从事医药制造业 为主的企业。企业注册资本10000万人民币。通过天眼查大数据分析，成大生物（本溪）有限公司参与 招投标项目21次 ...

| 证券简称：成大生物 公告编号：2025-046 | | 证券代码：688739 | | --- | --- | --- | | 辽宁成大生物股份有限公司 | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 | | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | 根据《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律 | | | | 2021 年 10 月 | | | | 度》等规范性文件的规定，辽宁成大生物股份有限公司（以下简称"成大生 | | | | 2025 年半年度的 | | 物"或"公司"）董事会就公司首次公开发行股票募集资金在 | | 2025 年半年度募集资金存放与使用情况专项报告 | | 使用情况进行了全面核查，对 说明如下： | | 25 日出具了《验资报告》（容诚验字[2021]110Z0015 号）。 | 验，于 | | | 一、募集资金的基本情况 | | | | 实际募集资金金额和资金到账时间 | | （一） | | 报告期内募集资金使用和结余情况 | | （二） | | 大生物股份有限公司首次公开 ...

Meeting Details - The shareholders' meeting of Liaoning Chengda Biological Co., Ltd. was held on August 28, 2025, in Shenyang, Liaoning Province [1] - A total of 223 ordinary shareholders attended the meeting, holding 240,348,641 voting rights, which accounts for 57.71% of the company's total voting rights [1] Voting Results - All proposed resolutions were passed with significant support from shareholders. For instance, the resolution regarding the election of Xu Biao as a non-independent director received 99.38% approval from ordinary shareholders [2] - The voting results for other resolutions also showed strong support, with percentages ranging from 98.63% to 99.38% in favor [2][2] Legal Compliance - The meeting was convened and conducted in accordance with the relevant laws and regulations, as confirmed by the attending lawyers [2][3]

Core Viewpoint - The report highlights the financial performance and operational challenges faced by Liaoning Chengda Biotechnology Co., Ltd. in the first half of 2025, indicating a significant decline in revenue and profit due to market competition and changes in vaccine demand [3][4][13]. Company Overview and Financial Indicators - Liaoning Chengda Biotechnology Co., Ltd. is primarily engaged in the research, production, and sales of human vaccines, classified under the pharmaceutical manufacturing industry [3][4]. - The company reported a revenue of approximately 706.78 million yuan, a decrease of 19.75% compared to the same period last year [4][13]. - The total profit for the period was approximately 145.96 million yuan, down 46.37% year-on-year, with net profit attributable to shareholders at approximately 122.29 million yuan, a decline of 44.47% [4][13]. - The company's net assets decreased by 2.16% to approximately 9.36 billion yuan, and total assets fell by 2.64% to approximately 9.79 billion yuan [4][13]. Industry Context - The vaccine industry in China is undergoing structural adjustments and upgrades, with a dual management system focusing on public health strategies [6][7]. - The global vaccine market is experiencing rapid growth, with a projected compound annual growth rate of 9.5% due to increased demand and technological advancements [5][6]. - The domestic vaccine market is characterized by intense competition, with over 70 licensed companies, contrasting sharply with the oligopolistic structure seen in the international market [7][9]. Business Operations and Market Position - The company maintains a leading position in the domestic and international markets for human rabies vaccines, supported by a robust sales network and strategic marketing initiatives [11][12][13]. - The company is the only domestic producer of inactivated Japanese encephalitis vaccine, which is gaining market traction through enhanced promotion and distribution efforts [10][12][17]. - The company has a strong research and development pipeline, focusing on various vaccine products, including human diploid rabies vaccine and multi-valent influenza vaccines, to meet market demands [12][17]. Strategic Initiatives - The company is implementing a dual-driven model for domestic and international market expansion, leveraging a self-operated sales team and local partnerships [11][12][15]. - The marketing strategy emphasizes channel consolidation and terminal expansion, with a focus on increasing penetration in community hospitals and health clinics [15][16][17]. - The company is actively pursuing international market opportunities, particularly in developing countries, supported by the "Belt and Road" initiative [11][12][15].

Group 1 - The core viewpoint of the report indicates a decline in key financial metrics for the first half of 2025 compared to the same period in the previous year, highlighting challenges faced by the company [1][2] - Total assets at the end of the reporting period were approximately 9.79 billion RMB, a decrease of 2.64% from the previous year-end [1] - Operating revenue for the period was approximately 706.78 million RMB, reflecting a significant decline of 19.75% compared to 880.69 million RMB in the same period last year [1] - Total profit for the period was approximately 145.96 million RMB, down 46.37% from 272.15 million RMB in the previous year [1] - The net profit attributable to shareholders was reported at approximately 0.30 RMB per share, a decrease of 43.40% from the previous year [2] Group 2 - The company reported a weighted average return on net assets of 1.28%, down from 2.29%, indicating a decrease of 1.01 percentage points [1] - The number of shareholders at the end of the reporting period was 25,344 [2] - The actual controller of the company changed from the Liaoning Provincial State-owned Assets Supervision and Administration Commission to no actual controller as of February 28, 2025 [5]